| Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility H Xu, BO Wang, M Ono, A Kagita, K Fujii, N Sasakawa, T Ueda, P Gee, ... Cell stem cell 24 (4), 566-578. e7, 2019 | 519 | 2019 |
| Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping P Gee, MSY Lung, Y Okuzaki, N Sasakawa, T Iguchi, Y Makita, H Hozumi, ... Nature communications 11 (1), 1334, 2020 | 311 | 2020 |
| CRISPR-Cas3 induces broad and unidirectional genome editing in human cells H Morisaka, K Yoshimi, Y Okuzaki, P Gee, Y Kunihiro, E Sonpho, H Xu, ... Nature communications 10 (1), 5302, 2019 | 178 | 2019 |
| Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells B Wang, S Iriguchi, M Waseda, N Ueda, T Ueda, H Xu, A Minagawa, ... Nature biomedical engineering 5 (5), 429-440, 2021 | 135 | 2021 |
| iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and natural killer cell immunity D Suzuki, C Flahou, N Yoshikawa, I Stirblyte, Y Hayashi, A Sawaguchi, ... Stem cell reports 14 (1), 49-59, 2020 | 67 | 2020 |
| Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells T Ueda, S Shiina, S Iriguchi, S Terakura, Y Kawai, R Kabai, S Sakamoto, ... Nature Biomedical Engineering 7 (1), 24-37, 2023 | 51 | 2023 |
| Cellular reprogramming, genome editing, and alternative CRISPR Cas9 technologies for precise gene therapy of Duchenne muscular dystrophy P Gee, H Xu, A Hotta Stem cells international 2017 (1), 8765154, 2017 | 50 | 2017 |
| Efficient ssODN-mediated targeting by avoiding cellular inhibitory RNAs through precomplexed CRISPR-Cas9/sgRNA ribonucleoprotein A Kagita, MSY Lung, H Xu, Y Kita, N Sasakawa, T Iguchi, M Ono, ... Stem Cell Reports 16 (4), 985-996, 2021 | 42 | 2021 |
| Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application Y Kitano, S Nishimura, TM Kato, A Ueda, K Takigawa, M Umekage, ... Molecular Therapy-Methods & Clinical Development 26, 15-25, 2022 | 37 | 2022 |
| Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles Y Zhitnyuk, P Gee, MSY Lung, N Sasakawa, H Xu, H Saito, A Hotta Biochemical and Biophysical Research Communications 505 (4), 1097-1102, 2018 | 30 | 2018 |
| Site-specific randomization of the endogenous genome by a regulatable CRISPR-Cas9 piggyBac system in human cells K Ishida, H Xu, N Sasakawa, MSY Lung, JA Kudryashev, P Gee, A Hotta Scientific Reports 8 (1), 310, 2018 | 28 | 2018 |
| Optimized electroporation of CRISPR-Cas9/gRNA ribonucleoprotein complex for selection-free homologous recombination in human pluripotent stem cells H Xu, Y Kita, U Bang, P Gee, A Hotta STAR protocols 2 (4), 100965, 2021 | 19 | 2021 |
| CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. Nat Commun 10: 5302 H Morisaka, K Yoshimi, Y Okuzaki, P Gee, Y Kunihiro, E Sonpho, H Xu, ... | 5 | 2019 |
| Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells C Flahou, T Morishima, N Higashi, Y Hayashi, H Xu, B Wang, C Zhang, ... Biochemical and Biophysical Research Communications 662, 76-83, 2023 | 1 | 2023 |
| Method for producing low-antigenic cell A Hotta, H Xu, S Kaneko, B Wang US Patent App. 16/969,222, 2020 | 1 | 2020 |
| Genetically modified megakaryocyte, modified platelet, and methods respectively for producing said genetically modified megakaryocyte and said modified platelet Y Harada, A Hotta, H Xu, N Sugimoto, K Eto US Patent App. 17/797,551, 2023 | | 2023 |
| AMPK-p38 axis converts human pluripotent stem cells to naïve state Z Yang, Y Liu, H Xu, J Yamane, A Hotta, W Fujibuchi, JK Yamashita bioRxiv, 2022.03. 31.486536, 2022 | | 2022 |
| Method for inducing deletion in genomic dna A Hotta, Y Okuzaki, H Xu, PD Gee, K Yuto, T Mashimo, K Yoshimi US Patent App. 17/309,607, 2022 | | 2022 |
| Nanomembrane-Derived Extracellular Vesicles for the Delivery of Crispr-Cas9/Grna for Therapeutic Exon Skipping in Duchenne Muscular Dystrophy A Hotta, P Gee, MSY Lung, Y Okuzaki, N Sasakawa, T Iguchi, Y Makita, ... MOLECULAR THERAPY 28 (4), 565-565, 2020 | | 2020 |
| Enhanced stealth property on iPSC to generate universal T cell source for allogeneic cancer immunotherapy B Wang, S Iriguchi, H Xu, M Waseda, T Ueda, A Minagawa, N Ueda, ... EUROPEAN JOURNAL OF IMMUNOLOGY 49, 1788-1788, 2019 | | 2019 |
